Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 7-Day Trial for You or Your Team.

Learn More →

Previous cancers in women diagnosed with premature ovarian insufficiency: A nationwide population‐based case–control study

Previous cancers in women diagnosed with premature ovarian insufficiency: A nationwide... AbbreviationsCIconfidence intervalFCRFinnish Cancer RegistryHRThormone replacement therapyICD‐O‐3International Classification of Diseases for Oncology, third editionORodds ratioPOIpremature ovarian insufficiencyKey messageOne in five women with premature ovarian insufficiency (POI) had a history of cancer. The prevalence of cancer among women with POI was more than 27 times higher than among controls in the Finnish population. The risk of POI among cancer patients was highest within 2 years of cancer diagnosis.INTRODUCTIONPremature ovarian insufficiency (POI) is defined as amenorrhea for at least 4 months and high follicle‐stimulating hormone levels in two separate samples from a woman younger than 40 years.1 The prevalence of POI is reported to be 1%–3%, and in a recent study, we reported a cumulative incidence of approximately 0.5%.2,3 The impact of POI on women's health is far‐reaching, causing fertility impairment and long‐term bone, cardiovascular, and cognitive health deterioration.4,5Genetic, iatrogenic, or autoimmune causes can lead to POI. However, the etiology remains unknown in most patients, even after extensive screening.6 A genetic etiological factor is found in 7%–30% of patients, and autoimmune diseases have been linked to 4%–30% of POI cases.4,7,8 In a recent register‐based study, we found that 15.9% of POI patients had a genetic disorder or congenital malformation. The overall prevalence of Turner syndrome http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Acta Obstetricia Et Gynecologica Scandinavica Wiley

Previous cancers in women diagnosed with premature ovarian insufficiency: A nationwide population‐based case–control study

Download PDF
8 pages

Loading next page...
 
/lp/wiley/previous-cancers-in-women-diagnosed-with-premature-ovarian-4xWFd0vMZU

References (35)

Publisher
Wiley
Copyright
Copyright © 2024 Acta Obstetricia et Gynecologica Scandinavica
ISSN
0001-6349
eISSN
1600-0412
DOI
10.1111/aogs.14783
Publisher site
See Article on Publisher Site

Abstract

AbbreviationsCIconfidence intervalFCRFinnish Cancer RegistryHRThormone replacement therapyICD‐O‐3International Classification of Diseases for Oncology, third editionORodds ratioPOIpremature ovarian insufficiencyKey messageOne in five women with premature ovarian insufficiency (POI) had a history of cancer. The prevalence of cancer among women with POI was more than 27 times higher than among controls in the Finnish population. The risk of POI among cancer patients was highest within 2 years of cancer diagnosis.INTRODUCTIONPremature ovarian insufficiency (POI) is defined as amenorrhea for at least 4 months and high follicle‐stimulating hormone levels in two separate samples from a woman younger than 40 years.1 The prevalence of POI is reported to be 1%–3%, and in a recent study, we reported a cumulative incidence of approximately 0.5%.2,3 The impact of POI on women's health is far‐reaching, causing fertility impairment and long‐term bone, cardiovascular, and cognitive health deterioration.4,5Genetic, iatrogenic, or autoimmune causes can lead to POI. However, the etiology remains unknown in most patients, even after extensive screening.6 A genetic etiological factor is found in 7%–30% of patients, and autoimmune diseases have been linked to 4%–30% of POI cases.4,7,8 In a recent register‐based study, we found that 15.9% of POI patients had a genetic disorder or congenital malformation. The overall prevalence of Turner syndrome

Journal

Acta Obstetricia Et Gynecologica Scandinavica – Wiley

Published: May 1, 2024

Keywords: cancer; cancer survivor; early menopause; premature ovarian insufficiency; young adult cancer

There are no references for this article.